Filing Details
- Accession Number:
- 0001140361-21-033351
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-01 21:18:16
- Reporting Period:
- 2021-10-01
- Accepted Time:
- 2021-10-01 21:18:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1559053 | Prothena Corp Public Ltd Co | PRTA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1582306 | J. Dennis Selkoe | C/O Prothena Biosciences Inc 331 Oyster Point Boulevard South San Francisco CA 94080 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, Par Value $0.01 Per Share | Acquisiton | 2021-10-01 | 5,000 | $9.23 | 7,845 | No | 4 | M | Direct | |
| Ordinary Shares, Par Value $0.01 Per Share | Disposition | 2021-10-01 | 1,757 | $66.35 | 6,088 | No | 4 | S | Direct | |
| Ordinary Shares, Par Value $0.01 Per Share | Disposition | 2021-10-01 | 1,300 | $67.96 | 4,788 | No | 4 | S | Direct | |
| Ordinary Shares, Par Value $0.01 Per Share | Disposition | 2021-10-01 | 1,237 | $68.74 | 3,551 | No | 4 | S | Direct | |
| Ordinary Shares, Par Value $0.01 Per Share | Disposition | 2021-10-01 | 706 | $69.69 | 2,845 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Stock Option (Right to Buy) | Disposition | 2021-10-01 | 5,000 | $0.00 | 5,000 | $9.23 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 11,000 | 2020-05-18 | 2029-05-22 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Ordinary Shares, Par Value $0.01 Per Share | 1,363 | Indirect | By wife |
Footnotes
- The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- The transaction was executed in multiple trades in prices ranging from $66.14 to $67.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $67.33 to $68.26, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $68.44 to $69.30, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $69.49 to $70.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Billionaire Hedge Funds
